130 related articles for article (PubMed ID: 18197124)
1. The pharmacokinetics and viral activity of tenofovir in the male genital tract.
Vourvahis M; Tappouni HL; Patterson KB; Chen YC; Rezk NL; Fiscus SA; Kearney BP; Rooney JF; Hui J; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2008 Mar; 47(3):329-33. PubMed ID: 18197124
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.
Ruane PJ; DeJesus E; Berger D; Markowitz M; Bredeek UF; Callebaut C; Zhong L; Ramanathan S; Rhee MS; Fordyce MW; Yale K
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):449-55. PubMed ID: 23807155
[TBL] [Abstract][Full Text] [Related]
3. Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults.
Baheti G; King JR; Acosta EP; Fletcher CV
AIDS; 2013 Jan; 27(2):221-5. PubMed ID: 23032419
[TBL] [Abstract][Full Text] [Related]
4. Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.
Goicoechea M; Jain S; Bi L; Kemper C; Daar ES; Diamond C; Ha B; Flaherty J; Sun S; Richman D; Louie S; Haubrich R;
AIDS; 2010 Mar; 24(5):707-16. PubMed ID: 20087154
[TBL] [Abstract][Full Text] [Related]
5. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
Hawkins T; Veikley W; Durand-Gasselin L; Babusis D; Reddy YS; Flaherty JF; Ray AS
Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
[TBL] [Abstract][Full Text] [Related]
6. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Hawkins T; Veikley W; St Claire RL; Guyer B; Clark N; Kearney BP
J Acquir Immune Defic Syndr; 2005 Aug; 39(4):406-11. PubMed ID: 16010161
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.
Duwal S; Schütte C; von Kleist M
PLoS One; 2012; 7(7):e40382. PubMed ID: 22808148
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients.
Valade E; Bouazza N; Lui G; Illamola SM; Benaboud S; Treluyer JM; Cobat A; Foissac F; De Sousa Mendes M; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Urien S; Ghosn J; Hirt D
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956420
[TBL] [Abstract][Full Text] [Related]
9. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).
Hirt D; Ekouévi DK; Pruvost A; Urien S; Arrivé E; Blanche S; Avit D; Amani-Bosse C; Nyati M; Legote S; Ek ML; Say L; McIntyre J; Dabis F; Tréluyer JM
Antimicrob Agents Chemother; 2011 Jun; 55(6):2961-7. PubMed ID: 21464249
[TBL] [Abstract][Full Text] [Related]
10. Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.
Baheti G; Kiser JJ; Havens PL; Fletcher CV
Antimicrob Agents Chemother; 2011 Nov; 55(11):5294-9. PubMed ID: 21896913
[TBL] [Abstract][Full Text] [Related]
11. A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate.
Yang KH; Hendrix C; Bumpus N; Elliott J; Tanner K; Mauck C; Cranston R; McGowan I; Richardson-Harman N; Anton PA; Kashuba AD
PLoS One; 2014; 9(10):e106196. PubMed ID: 25350119
[TBL] [Abstract][Full Text] [Related]
12. Models for predicting effective HIV chemoprevention in women.
Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
[TBL] [Abstract][Full Text] [Related]
13. Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study.
Chen J; Flexner C; Liberman RG; Skipper PL; Louissaint NA; Tannenbaum SR; Hendrix CW; Fuchs EJ
J Acquir Immune Defic Syndr; 2012 Dec; 61(5):593-9. PubMed ID: 23187888
[TBL] [Abstract][Full Text] [Related]
14. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
15. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
[TBL] [Abstract][Full Text] [Related]
16. Nucleotide analogue prodrug tenofovir disoproxil enhances lymphoid cell loading following oral administration in monkeys.
Durand-Gasselin L; Van Rompay KK; Vela JE; Henne IN; Lee WA; Rhodes GR; Ray AS
Mol Pharm; 2009; 6(4):1145-51. PubMed ID: 19545170
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.
Benaboud S; Hirt D; Launay O; Pannier E; Firtion G; Rey E; Bouazza N; Foissac F; Chappuy H; Urien S; Tréluyer JM
Antimicrob Agents Chemother; 2012 Feb; 56(2):857-62. PubMed ID: 22123690
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings.
Moss JA; Baum MM; Malone AM; Kennedy S; Kopin E; Nguyen C; Gilman J; Butkyavichene I; Willis RA; Vincent KL; Motamedi M; Smith TJ
AIDS; 2012 Mar; 26(6):707-10. PubMed ID: 22210639
[TBL] [Abstract][Full Text] [Related]
19. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis.
Johnson TJ; Clark MR; Albright TH; Nebeker JS; Tuitupou AL; Clark JT; Fabian J; McCabe RT; Chandra N; Doncel GF; Friend DR; Kiser PF
Antimicrob Agents Chemother; 2012 Dec; 56(12):6272-83. PubMed ID: 23006751
[TBL] [Abstract][Full Text] [Related]
20. A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel.
Schwartz JL; Rountree W; Kashuba AD; Brache V; Creinin MD; Poindexter A; Kearney BP
PLoS One; 2011; 6(10):e25974. PubMed ID: 22039430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
